ClinicalTrials.gg
RecruitingNCT05640089Updated Oct 13, 2026

FMRI-neurofeedback in Depression

An interventional study of fMRI-based neurofeedback in Depression, Unipolar, sponsored by Maastricht University Medical Center. Recruiting at 3 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 9 months later.
Updated Oct 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Depressive Disorder with a site in Netherlands — 7 open to participants now, 9 under way, none of them phase 3. Depressive Disorder · Netherlands.

Planned enrollment
9th of 16
120 · median 151
Started
2023
with 1 other
No phase
9 of 18
6 open now
Registered
12th of 18
by date
Lead sponsor
2 of 18
Maastricht University Medical Center

Among the 18 studies in Depressive Disorder with a site in Netherlands, this one is the 9th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2023, is one of 9 with no phase, and was the 12th registered.

Depressive Disorder

857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

7 of the 18 studies in Depressive Disorder with a site in Netherlands are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Depressive Disorder with a site in Netherlands, or all of them as a file.
02

Study summary

Previous studies with fMRI-neurofeedback in depression have demonstrated a good safety profile and considerable symptom reduction. The goal of this clinical trial is to compare fMRI-neurofeedback plus standard care with standard care in patients with depression.

Participants will either receive standard care, or standard care plus a fMRI neurofeedback training, consisting of 5 neurofeedback training sessions. Symptom severity will be assessed before, immediately after and 6 months after the intervention.

Read the detailed description

Rationale: Previous studies with fMRI-neurofeedback in depression have demonstrated a good safety profile and considerable symptom reduction but a comparison between standard care and standard care plus fMRI-neurofeedback has not yet been carried out.

Objective: To assess the efficacy of fMRI-neurofeedback plus standard care in comparison with standard care in patients with depression.

Study design: Single-blind RCT. Patients will be randomly allocated to fMRI-neurofeedback plus standard care or standard care. Assessments will be conducted by assessors who are blinded to group allocation.

Patients will be randomised to the two groups using a block randomisation procedure (10 participants per block). Depression severity at baseline (IDS scores) will be used as minimisation variable to ensure equal severity in both groups. The study team will receive a code for group allocation. The study team and patient will be aware of the group allocation (by the nature of the study design), but assessors performing baseline, post-intervention and follow-up assessments will be blinded. During interim analyses, the analysts will remain blinded to the conditions.

If the stopping criterion is reached before the maximal N, any patients already randomised will complete the study and their data will be included in the secondary analyses.

Study population: Currently symptomatic adult patients with depression.

Sample size calculation: A Sequential Bayes Factor (SBF) sampling plan will be used. SBF allows accumulating evidence for (or against) an effect until a certain threshold, i.e. a Bayes Factor (BF), or max N is reached. This is one main advantage compared to frequentist statistics (which is biased against the null hypothesis). Moreover, type-I and type-II error rates do not exist, allowing for flexible stopping rules. This property renders SBF a more resource efficient (in particular for small to medium effect sizes) compared to (traditional frequentist) fixed-N sampling plans. Since type-II errors do not exist in Bayesian statistics, there is no concept of statistical power as in traditional frequentist statistics. However, sensitivity analyses can be carried out a priori to help determining the sample size required to reach a pre-declared level of evidence (given an assumed effect size and a specific prior distribution) that serves as a stopping criterion, For the current sampling plan a BF >= 6 (for either the alternative or the null hypothesis) will be used as a stopping criterion, a value that is in line with recent recommendations. The analysis is carried out with an informed prior t-distribution (t(μ = 0.35, df = 3, r = 0.102)), which reflects a moderate effect size that the investigators would expect given the current design and is in line with suggested informed prior distributions in Psychology. The first interim analysis will be carried out with a minimum N=26 patients per group who have completed the primary endpoint. This minimum N is in line with recommendations for SBF sampling plans. If a BF of 6 for either the alternative or the null is hypothesis is not met, sequential sampling will be carried out with interim tests for every new patient who completes the primary endpoint until either the BF stopping criterion is met or a maximum N=38 is reached (max N). An effect size of Cohen's d = 0.6 was set as the smallest effect size of interest given the restricted resources and previously reported effect sizes reported by pre-registered randomised clinical trials of emotion self-regulation based fMRI neurofeedback. An N max of 38 per group yields 80% sensitivity to detect an effect size of 0.6 under flexible stopping as suggested by simulations (Monte Carlo with 10,000 iterations). Hence, such design is more resource efficient compared to a traditional frequentist fixed-N design (which requires N=45 to reach 80% sensitivity to detect an effect size Cohen's d = 0.6). Further, the false negative rate (i.e. the probability to accumulate erroneously sufficient evidence against the effect and stop the trial early) is only 0.1%, the false positive rate is 12%. The investigators accept this higher false positive rate (compared to the nominal 5%) given that the technology is safe to use. If the BF reaches a value BF>=3 (but smaller than 6) for either the alter-native or null hypothesis, the investigators will revaluate available resources for a potential third sampling phase with N max of 60 per group. The sampling plan thus follows recent recommendations of best practice.

Intervention: FMRI-neurofeedback will be administered in 5 sessions of about 1 hour each, each including a visual stimulation protocol for the localisation of areas responsive to positive emotions and appr. 30 minutes of upregulation training of these areas by means of neurofeedback, using real-time fMRI signals.

Main study parameters/endpoints:

Primary outcome: symptom severity (measured by the clinician-administered Inventory of Depressive Symptomatology) after the intervention.

Secondary outcomes: measures of depression, anxiety and general mental health (Beck Depression Inventory, Self-Efficacy Scale, Hospital Anxiety and Depression Scale, Quality Of Life scale and EuroQol research foundation questionnaire), predictive value of several trait measures (moderator analysis), changes in brain activation patterns measured by fMRI for the neurofeedback group.

In the analysis, outcomes will be controlled for the measurements at baseline.

03

Conditions studied

  • Depression, Unipolar

Keywords

  • Depression
  • Depressive Disorder
  • Behavioral Symptoms
  • Mood Disorders
  • Mental Disorders
  • fMRI Neurofeedback
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of a depressive disorder (ICD-10: F32 or F33)
  • Has been on stable antidepressant medication (single or combination treatment) for at least 4 weeks
  • Current depression (QIDS >= 17)
  • If required to meet recruitment targets the minimum entry score will be reduced QIDS >= 13 (i.e. still corresponding to a moderate level of depression)

Exclusion criteria

Exclusion Criteria:

  • Exclusion criteria for MRI (e.g. cardiac pacemaker, certain metallic implants)
  • History of psychotic disorder bipolar disorder, or psychotic depression
  • Current use of illegal drugs (any in the last four weeks)
  • Current excessive alcohol consumption that interferes with daily functioning
  • History of neurological disease that could influence the fMRI signal and/or the anatomical alignment (e.g. territorial stroke, multiple sclerosis, brain tumour)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Emotion network up-regulation + standard care

    NF protocol targeting emotion networks (NFE) (plus standard care)

    Other: fMRI-based neurofeedback

  • No intervention
    Standard care

    Continuation of treatment as usual.

Interventions

  • OtherfMRI-based neurofeedback

    Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).

06

What researchers measure

Primary outcomes

  1. Post-intervention score for the 30 item Inventory of Depressive Symptomatology (IDS)

    30 item clinician rated depression scale (Rush et al., 1986; Rush, Gullion, Basco, Jarrett, \& Trivedi, 1996)

    Time frame: End of intervention: appr. 2 months after baseline

Secondary outcomes

  1. Six month follow-up score for the 30 item Inventory of Depressive Symptomatology (IDS)

    30 item clinician rated depression scale (Rush et al., 1986; Rush, Gullion, Basco, Jarrett, \& Trivedi, 1996)

    Time frame: 6-month follow-up

  2. Post-intervention score for the Beck Depression Inventory (BDI)

    Self-rated depression scale (Beck, Steer, \& Brown, 1996)

    Time frame: End of intervention: appr. 2 months after baseline

  3. Six month follow-up score for the Beck Depression Inventory (BDI)

    Self-rated depression scale (Beck, Steer, \& Brown, 1996)

    Time frame: 6-month follow-up

  4. Post-intervention score for the Hospital Anxiety and Depression Scale (HADS)

    Self-rated depression and anxiety scale (Zigmond \& Snaith, 1983). The questionnaire comprises 7 questions for anxiety and 7 for depression. Each scale has a minumum score of 0 and a maximum score of 21. A higher score means more severe anxiety- or depression complaints.

    Time frame: End of intervention: appr. 2 months after baseline

  5. Six month follow-up score for the Hospital Anxiety and Depression Scale (HADS)

    Self-rated depression and anxiety scale (Zigmond \& Snaith, 1983). The questionnaire comprises 7 questions for anxiety and 7 for depression. Each scale has a minumum score of 0 and a maximum score of 21. A higher score means more severe anxiety- or depression complaints.

    Time frame: 6-month follow-up

  6. Post-intervention score for the Quality Of Life scale (QOLS)

    Self-rated quality of life scale. A higher score reflects a better quality of life.

    Time frame: End of intervention: appr. 2 months after baseline

  7. Six month follow-up score for the Quality Of Life scale (QOLS)

    Self-rated quality of life scale. A higher score reflects a better quality of life.

    Time frame: 6-month follow-up

  8. Post-intervention score for the EuroQol research foundation questionnaire (EQ-5D-5L)

    Self-rated scale of five dimensions of health (Brooks \& Group, 1996)

    Time frame: End of intervention: appr. 2 months after baseline

  9. Six month follow-up score for the EuroQol research foundation questionnaire (EQ-5D-5L)

    Self-rated scale of five dimensions of health (Brooks \& Group, 1996)

    Time frame: 6-month follow-up

  10. Experience sampling of mood states, somatic symptoms and activities using the PsyMate application

    One week after baseline and one week before the end of intervention measurement partic-ipants will undergo an experience sampling procedure. Experience sampling will be acquired through the PsyMate application (https://www.psymate.eu) on patients' own or provided smartphones. Participants will thereby digitally complete a brief questionnaire including current affect (positive affect and negative affect items) as well as current context and activ-ities ("daily life activities", "persons present", "physical activity", and "events")

    Time frame: 1 week after baseline, 1 week before the end of intervention measurement

  11. Post-intervention score for the Self Efficacy Scale (SES)

    Self-rated scale assessing self efficacy (Sherer et al., 1982). The total scores range from 10 to 40. A higher score means more self-efficacy.

    Time frame: End of intervention: appr. 2 months after baseline

  12. Six month follow-up score for the Self Efficacy Scale (SES)

    Self-rated scale assessing self efficacy (Sherer et al., 1982). The total scores range from 10 to 40. A higher score means more self-efficacy.

    Time frame: 6-month follow-up

Other outcomes

  1. Ability to self-regulate the target region-of-interest during neurofeedback training

    Determine whether participants are able to modulate their BOLD activity in keeping with the neurofeedback

    Time frame: Each scanning session (appr. 2 months: session 1: week 1; session 2: week 2; session 3: week 3; session 4: week 4; session 5: week 8)

  2. Changes in functional parameters (as measured by fMRI) of emotion networks over the course of the intervention

    Analysis of fMRI data

    Time frame: Each scanning session (appr. 2 months: session 1: week 1; session 2: week 2; session 3: week 3; session 4: week 4; session 5: week 8)

  3. Brain network activity during neurofeedback training (fMRI analysis)

    Determining changes in brain networks (e.g. default mode network)

    Time frame: Each scanning session (appr. 2 months: session 1: week 1; session 2: week 2; session 3: week 3; session 4: week 4; session 5: week 8)

  4. Changes in Profile of Mood States (POMS) after neurofeedback sessions

    Measure to address any imminent changes in mood state

    Time frame: Before and after each scanning session (appr. 2 months: session 1: week 1; session 2: week 2; session 3: week 3; session 4: week 4; session 5: week 8)

07

Study locations

3 of 3 sites recruiting
  • Mondriaan Zorggroep
    Maastricht, 6226NB, Netherlands
    Recruiting
    • Rob Havermans, Dr. · Contact
  • Maastricht University
    Maastricht, 6229ER, Netherlands
    Recruiting
  • Maastricht UMC+
    Maastricht, 6229HX, Netherlands
    Recruiting
    • Bart Rutten, Professor · Contact
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Apr 2027, 51 months after the start.

Of 261 non-industry interventional studies with no phase under Depressive Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 51 months is above that.

Counting every sponsor, half of 276 studies reached it within 29 months; a quarter within 15 and three quarters within 45.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Dec 2026 → Apr 2027 and completion Apr 2027 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2022
First posted
Dec 7, 2022
StartActual
Jan 25, 2023
Primary completionEst.
Apr 30, 2027was Dec 2026
CompletionEst.
Jul 31, 2027was Apr 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Apr 30, 2027
Oct 13, 2026
Study completion
Apr 30, 2027→Jul 31, 2027
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Dec 31, 2026→Apr 30, 2027
    Study completion Apr 30, 2027→Jul 31, 2027
    + 4 other changes: identifiers, verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05640089
Responsible party
Sponsor
First posted
Dec 7, 2022
Start date
Jan 25, 2023
Primary completion
Apr 30, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

David E Linden, Prof.
Contact
david.linden@maastrichtuniversity.nl
+31 43 3881021
David E Linden, Prof.
principal investigator · Professor of Translational Neuroscience

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion